These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 33971042)
1. Early Discrimination Between Tumor-Induced Rickets/Osteomalacia and X-Linked Hypophosphatemia in Chinese Children and Adolescents: A Retrospective Case-Control Study. Jiajue R; Ni X; Jin C; Huo L; Wu H; Liu Y; Jin J; Yu W; Lv W; Zhou L; Xia Y; Chi Y; Cui L; Pang Q; Li X; Jiang Y; Wang O; Li M; Xing X; Meng X; Xia W J Bone Miner Res; 2021 Sep; 36(9):1739-1748. PubMed ID: 33971042 [TBL] [Abstract][Full Text] [Related]
2. Bone Volumetric Density, Microarchitecture, and Estimated Bone Strength in Tumor-Induced Rickets/Osteomalacia Jiajue R; Ni X; Jin C; Yu W; Huo L; Wu H; Liu Y; Jin J; Lv W; Zhou L; Xia Y; Chi Y; Cui L; Pang Q; Li X; Jiang Y; Wang O; Li M; Xing X; Meng X; Xia W Front Endocrinol (Lausanne); 2022; 13():883981. PubMed ID: 35769089 [TBL] [Abstract][Full Text] [Related]
3. X-Linked Hypophosphatemia: Uniquely Mild Disease Associated With PHEX 3'-UTR Mutation c.*231A>G (A Retrospective Case-Control Study). Smith PS; Gottesman GS; Zhang F; Cook F; Ramirez B; Wenkert D; Wollberg V; Huskey M; Mumm S; Whyte MP J Bone Miner Res; 2020 May; 35(5):920-931. PubMed ID: 31910300 [TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries. Al Juraibah F; Al Amiri E; Al Dubayee M; Al Jubeh J; Al Kandari H; Al Sagheir A; Al Shaikh A; Beshyah SA; Deeb A; Habeb A; Mustafa M; Zidan H; Mughal MZ Arch Osteoporos; 2021 Mar; 16(1):52. PubMed ID: 33660084 [TBL] [Abstract][Full Text] [Related]
5. Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23. Ito N; Kubota T; Kitanaka S; Fujiwara I; Adachi M; Takeuchi Y; Yamagami H; Kimura T; Shinoda T; Minagawa M; Okazaki R; Ozono K; Seino Y; Fukumoto S J Bone Miner Metab; 2021 Nov; 39(6):1066-1075. PubMed ID: 34255195 [TBL] [Abstract][Full Text] [Related]
7. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia. Imanishi Y; Ito N; Rhee Y; Takeuchi Y; Shin CS; Takahashi Y; Onuma H; Kojima M; Kanematsu M; Kanda H; Seino Y; Fukumoto S J Bone Miner Res; 2021 Feb; 36(2):262-270. PubMed ID: 32967046 [TBL] [Abstract][Full Text] [Related]
8. New Therapies for Hypophosphatemia-Related to FGF23 Excess. Athonvarangkul D; Insogna KL Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139 [TBL] [Abstract][Full Text] [Related]
10. Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia. Hartley IR; Gafni RI; Roszko KL; Brown SM; de Castro LF; Saikali A; Ferreira CR; Gahl WA; Pacak K; Blau JE; Boyce AM; Salusky IB; Collins MT; Florenzano P J Bone Miner Res; 2022 Nov; 37(11):2174-2185. PubMed ID: 36093861 [TBL] [Abstract][Full Text] [Related]
11. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment. Kinoshita Y; Fukumoto S Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780 [TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of bone markers in hypophosphatemic rickets/osteomalacia. Nagata Y; Imanishi Y; Ishii A; Kurajoh M; Motoyama K; Morioka T; Naka H; Mori K; Miki T; Emoto M; Inaba M Endocrine; 2011 Oct; 40(2):315-7. PubMed ID: 21822687 [TBL] [Abstract][Full Text] [Related]
14. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment. Fukumoto S J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878 [TBL] [Abstract][Full Text] [Related]
15. Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium. Laurent MR; De Schepper J; Trouet D; Godefroid N; Boros E; Heinrichs C; Bravenboer B; Velkeniers B; Lammens J; Harvengt P; Cavalier E; Kaux JF; Lombet J; De Waele K; Verroken C; van Hoeck K; Mortier GR; Levtchenko E; Vande Walle J Front Endocrinol (Lausanne); 2021; 12():641543. PubMed ID: 33815294 [TBL] [Abstract][Full Text] [Related]
16. Low Levels of Serum Sclerostin in Adult Patients With Tumor-Induced Osteomalacia Compared With X-linked Hypophosphatemia. Ni X; Zhang Q; Li X; Pang Q; Gong Y; Wang O; Li M; Xing X; Jiang Y; Xia W J Clin Endocrinol Metab; 2022 Jan; 107(1):e361-e371. PubMed ID: 34363479 [TBL] [Abstract][Full Text] [Related]
17. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.]. Kinoshita Y Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120 [TBL] [Abstract][Full Text] [Related]
18. Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia. Giralt M; Chocron S; Ferrer R; Ariceta G Pediatr Nephrol; 2021 Apr; 36(4):1025-1028. PubMed ID: 33492457 [TBL] [Abstract][Full Text] [Related]